By M. Marin
Entering Fiscal 2022 With …
Last week Aethlon Medical (NASDAQ:AEMD) announced results for fiscal 2021 and provided a business update. The company also provided additional color around the recent findings that the Aethlon Hemopurifier® produced positive results in treating two patients who were critically ill with COVID-19.
… Enhanced financial flexibility
Importantly, AEMD finished fiscal 2021 with about $9.9 million in cash and no debt. In June 2021, AEMD raised an aggregate roughly $17.3 million. The funds enhance the company’s financial flexibility to advance clinical trials and move the Hemopurifier towards potential regulatory approval and commercial launch.
AEMD has two Early Feasibility Studies (EFS) of the Hemopurifier underway: one treating COVID patients and one treating patients with head and neck cancer. With two different studies of different diseases, we believe AEMD potentially has expanded the commercial opportunity for the device and possibly shortened the path to approval.
Moreover, the Hemopurifier® positive results in treating two critically ill COVID-19 patients augment the database of the Hemopurifier’s clinical benefits:
➢ Successfully cleared SARS-CoV-2 virus from the blood stream.
➢ Successfully cleared associated exosomes from the blood stream.
➢ Patients tolerated Hemopurifier treatment without side effects
➢ Lowered noxious exosomal microRNAs associated with coagulopathy and acute lung injury
And Potentially Expanded Commercial Opportunities
We believe the company continues to build its database of positive outcomes using the Hemopurifier. Over the years, AEMD has demonstrated that the Hemopurifier binds and removes glycosylated – or sugar coated – viruses. The Hemopurifier captures enveloped viral pathogens and exosomes in the circulating bloodstream, based on size and glycosylation, and removes them. The Hemopurifier has demonstrated clearance of many different viruses in vitro, including HIV, dengue, West Nile, influenza, Ebola, herpes and MERS.
The company believes the Hemopurifier can be applied to COVID-19 and potentially a range of other conditions. We believe the Hemopurfier results with the two COVID-19 patients noted above point to the potential versatility of the Hemopurfier that could, in turn, also imply a growing commercial opportunity for AEMD’s device.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.